DJB Labcare Limited 05365732 false 2023-01-01 2023-12-31 2023-12-31 The principal activity of the company is that of the sale, service and repair of laboratory equipment. Digita Accounts Production Advanced 6.30.9574.0 true 05365732 2023-01-01 2023-12-31 05365732 2023-12-31 05365732 bus:Director1 1 2023-12-31 05365732 core:CurrentFinancialInstruments 2023-12-31 05365732 core:CurrentFinancialInstruments core:WithinOneYear 2023-12-31 05365732 core:Goodwill 2023-12-31 05365732 core:OtherResidualIntangibleAssets 2023-12-31 05365732 core:FurnitureFittingsToolsEquipment 2023-12-31 05365732 core:MotorVehicles 2023-12-31 05365732 bus:SmallEntities 2023-01-01 2023-12-31 05365732 bus:AuditExemptWithAccountantsReport 2023-01-01 2023-12-31 05365732 bus:FilletedAccounts 2023-01-01 2023-12-31 05365732 bus:SmallCompaniesRegimeForAccounts 2023-01-01 2023-12-31 05365732 bus:RegisteredOffice 2023-01-01 2023-12-31 05365732 bus:CompanySecretaryDirector1 2023-01-01 2023-12-31 05365732 bus:Director1 2023-01-01 2023-12-31 05365732 bus:Director1 1 2023-01-01 2023-12-31 05365732 bus:Director2 2023-01-01 2023-12-31 05365732 bus:PrivateLimitedCompanyLtd 2023-01-01 2023-12-31 05365732 bus:Agent1 2023-01-01 2023-12-31 05365732 core:Goodwill 2023-01-01 2023-12-31 05365732 core:IntangibleAssetsOtherThanGoodwill 2023-01-01 2023-12-31 05365732 core:OtherResidualIntangibleAssets 2023-01-01 2023-12-31 05365732 core:ComputerEquipment 2023-01-01 2023-12-31 05365732 core:FurnitureFittings 2023-01-01 2023-12-31 05365732 core:FurnitureFittingsToolsEquipment 2023-01-01 2023-12-31 05365732 core:MotorVehicles 2023-01-01 2023-12-31 05365732 core:PlantMachinery 2023-01-01 2023-12-31 05365732 countries:EnglandWales 2023-01-01 2023-12-31 05365732 2022-12-31 05365732 bus:Director1 1 2022-12-31 05365732 core:Goodwill 2022-12-31 05365732 core:OtherResidualIntangibleAssets 2022-12-31 05365732 core:FurnitureFittingsToolsEquipment 2022-12-31 05365732 core:MotorVehicles 2022-12-31 05365732 2022-01-01 2022-12-31 05365732 2022-12-31 05365732 bus:Director1 1 2022-12-31 05365732 core:CurrentFinancialInstruments 2022-12-31 05365732 core:CurrentFinancialInstruments core:WithinOneYear 2022-12-31 05365732 core:Goodwill 2022-12-31 05365732 core:OtherResidualIntangibleAssets 2022-12-31 05365732 core:FurnitureFittingsToolsEquipment 2022-12-31 05365732 core:MotorVehicles 2022-12-31 05365732 bus:Director1 1 2022-01-01 2022-12-31 05365732 bus:Director1 1 2021-12-31 iso4217:GBP xbrli:pure

Registration number: 05365732

DJB Labcare Limited

Annual Report and Unaudited Filleted Financial Statements

for the Year Ended 31 December 2023

image-name
 

DJB Labcare Limited

Contents

Company Information

1

Accountants' Report

2

Balance Sheet

3 to 4

Notes to the Unaudited Financial Statements

5 to 11

 

DJB Labcare Limited

Company Information

Directors

Mr CD Bradnam

Mr DJ Bradnam

Mrs P Bradnam

Company secretary

Mrs P Bradnam

Registered office

Unit 10-12 Howard Way
Cromwell Business Park
Newport Pagnell
Buckinghamshire
MK16 9QS

Accountants

Michael J Emery & Co Limited
Chartered Accountants
22 St John Street
Newport Pagnell
Buckinghamshire
MK16 8HJ

 

Chartered Accountants' Report to the Board of Directors on the Preparation of the Unaudited Statutory Accounts of
DJB Labcare Limited
for the Year Ended 31 December 2023

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of DJB Labcare Limited for the year ended 31 December 2023 as set out on pages 3 to 11 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at
http://www.icaew.com/regulation.

This report is made solely to the Board of Directors of DJB Labcare Limited, as a body, in accordance with the terms of our instructions. Our work has been undertaken solely to prepare for your approval the accounts of DJB Labcare Limited and state those matters that we have agreed to state to the Board of Directors of DJB Labcare Limited, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than DJB Labcare Limited and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that DJB Labcare Limited has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of DJB Labcare Limited. You consider that DJB Labcare Limited is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of DJB Labcare Limited. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

......................................

Michael J Emery & Co Limited
Chartered Accountants
22 St John Street
Newport Pagnell
Buckinghamshire
MK16 8HJ

19 September 2024

 

DJB Labcare Limited

(Registration number: 05365732)
Balance Sheet as at 31 December 2023

Note

2023
£

(As restated)

2022
£

Fixed assets

 

Intangible assets

4

113,512

63,652

Tangible assets

5

54,110

2,890

 

167,622

66,542

Current assets

 

Stocks

6

354,790

297,204

Debtors

7

459,552

492,710

Cash at bank and in hand

 

298,658

569,602

 

1,113,000

1,359,516

Creditors: Amounts falling due within one year

8

(514,535)

(649,318)

Net current assets

 

598,465

710,198

Net assets

 

766,087

776,740

Capital and reserves

 

Called up share capital

200

200

Retained earnings

765,887

776,540

Shareholders' funds

 

766,087

776,740

For the financial year ending 31 December 2023 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Directors' responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

Approved and authorised by the Board on 19 September 2024 and signed on its behalf by:
 

 

DJB Labcare Limited

(Registration number: 05365732)
Balance Sheet as at 31 December 2023

.........................................
Mr CD Bradnam
Director

 

DJB Labcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

1

General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:
Unit 10-12 Howard Way
Cromwell Business Park
Newport Pagnell
Buckinghamshire
MK16 9QS

These financial statements were authorised for issue by the Board on 19 September 2024.

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A smaller entities - 'The Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland' and the Companies Act 2006 (as applicable to companies subject to the small companies' regime).

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Turnover

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company’s activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:
The amount of revenue can be reliably measured;
it is probable that future economic benefits will flow to the entity;
and specific criteria have been met for each of the company's activities.

Government grants

Government grants are accounted for under the accruals model. Grant income is recognised when the expenditure towards which the grant is intended to contribute is incurred.

Foreign currency transactions and balances

Transactions denominated in foreign currencies are translated into sterling and recorded at the rate of exchange ruling at the date of the transaction, except when covered by a forward exchange contract when the contracted rate is used. Balances at the year-end denominated in a foreign currency are translated into sterling at the rate of exchange ruling at the balance sheet date.

 

DJB Labcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

Tax

The tax expense for the period comprises current tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Plant and machinery

25% on cost

Fixtures and fittings

25% on cost

Motor vehicles

25% on cost

Office equipment

33% on cost

Goodwill

Goodwill arising on the acquisition of an entity represents the excess of the cost of acquisition over the company’s interest in the net fair value of the identifiable assets, liabilities and contingent liabilities of the entity recognised at the date of acquisition. Goodwill is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is held in the currency of the acquired entity and revalued to the closing rate at each reporting period date. Goodwill is amortised over its useful life, which shall not exceed ten years if a reliable estimate of the useful life cannot be made.

Intangible assets

Intangible assets are measured at cost less accumulated amortisation and any accumulated impairment losses.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Goodwill

On a straight line basis over 10 years

Website

On a straight line basis over 5 years

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

 

DJB Labcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first-in, first-out (FIFO) method.

The cost of finished goods and work in progress comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the inventories to their present location and condition. At each reporting date, stocks are assessed for impairment. If stocks are impaired, the carrying amount is reduced to its selling price less costs to complete and sell; the impairment loss is recognised immediately in profit or loss.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

A defined contribution plan is a pension plan under which fixed contributions are paid into a pension fund and the company has no legal or constructive obligation to pay further contributions even if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods.

Contributions to defined contribution plans are recognised as employee benefit expense when they are due. If contribution payments exceed the contribution due for service, the excess is recognised as a prepayment.

 

DJB Labcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

3

Staff numbers

The average number of persons employed by the company during the year, including directors, was 16 (2022 - 15).

4

Intangible assets

Goodwill
 £

Other intangible assets
 £

Total
£

Cost or valuation

At 1 January 2023

471,050

99,216

570,266

Additions acquired separately

-

77,448

77,448

At 31 December 2023

471,050

176,664

647,714

Amortisation

At 1 January 2023

471,050

35,564

506,614

Amortisation charge

-

27,588

27,588

At 31 December 2023

471,050

63,152

534,202

Carrying amount

At 31 December 2023

-

113,512

113,512

At 31 December 2022

-

63,652

63,652

 

DJB Labcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

5

Tangible assets

Furniture, fittings and equipment
 £

Motor vehicles
 £

Total
£

Cost or valuation

At 1 January 2023

68,621

19,778

88,399

Additions

10,978

51,029

62,007

Disposals

-

(19,383)

(19,383)

At 31 December 2023

79,599

51,424

131,023

Depreciation

At 1 January 2023

65,731

19,778

85,509

Charge for the year

3,345

7,442

10,787

Eliminated on disposal

-

(19,383)

(19,383)

At 31 December 2023

69,076

7,837

76,913

Carrying amount

At 31 December 2023

10,523

43,587

54,110

At 31 December 2022

2,890

-

2,890

6

Stocks

2023
£

(As restated)

2022
£

Inventory

354,790

297,204

 

DJB Labcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

7

Debtors

2023
£

2022
£

Trade debtors

348,325

377,552

Prepayments

52,437

42,235

Other debtors

2,214

445

Corporation tax repayable

12,903

17,778

Director's loan account

39,700

54,700

VAT Control account

3,973

-

459,552

492,710

8

Creditors

Creditors: amounts falling due within one year

2023
£

(As restated)

2022
£

Due within one year

Trade creditors

31,966

72,478

Accruals and deferred income

386,488

384,141

Other creditors

7,053

10,198

Corporation tax control

71,033

114,546

PAYE and NIC creditor

17,995

16,871

VAT Control account

-

51,084

514,535

649,318

 

DJB Labcare Limited

Notes to the Unaudited Financial Statements for the Year Ended 31 December 2023

9

Financial commitments, guarantees and contingencies

Amounts not provided for in the balance sheet

The total amount of financial commitments not included in the balance sheet is £240,625 (2022 - £70,875).

10

Related party transactions

2023

At 1 January 2023
£

Repayments by director
£

At 31 December 2023
£

Mr CD Bradnam

54,700

(15,000)

39,700

2022

At 1 January 2022
£

Repayments by director
£

At 31 December 2022
£

Mr CD Bradnam

65,700

(11,000)

54,700